Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evalu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Awan, Farrukh T., Schuh, Anna, Brown, Jennifer R., Furman, Richard R., Pagel, John M., Hillmen, Peter, Stephens, Deborah M., Woyach, Jennifer, Bibikova, Elena, Charuworn, Prista, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Linghu, Bolan, Patel, Priti, Wang, Min Hui, Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2019
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517672/
https://ncbi.nlm.nih.gov/pubmed/31088809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018030007
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak